Skip to main content
SpringerLink
Log in

Left ventricular hypertrophy reversal with labetalol and propranolol: A prospective, randomized, double-blind study

  • Clinical Trials
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Summary

Hypertensive patients with left ventricular hypertrophy (LVH) have increased cardiovascular morbidity and mortality. Experimental studies indicate the importance of both the alpha and beta components of the adrenergic nervous system in the development and reversal of LVH. Therefore labetalol (L), a combined alpha and beta blocker, and propranolol (P), a nonselective beta blocker, were evaluated in a randomized, double-blind study of 35 hypertensive patients with echocardiographic evidence of LVH. Following 2 weeks of placebo, L or P was titrated as needed and tolerated to maximum total daily doses of 1600 mg and 640 mg, respectively. A thiazide diuretic was added if necessary for blood pressure control. M-mode echocardiograms were performed at baseline and after 1, 3, 6 and 12 months of blood pressure control. The echocardiograms were read independently by two blinded observers for end-diastolic dimension and wall thicknesses, and left ventricular mass. Fractional shortening, cardiac output, and peripheral vascular resistance were derived using standard formulas.

Both drugs reduced blood pressure significantly and comparably. Significant changes in the echocardiographic measurements were observed as early as 1 month and usually persisted throughout the study. Both drugs decreased posterior wall thickness; however, only the decrease in propranolol group achieved statistical significance. Septal wall thickness was reduced by L at 3 and 12 months. End-diastolic dimension increased significantly in the L-treated group at 3, 6, and 12 months of therapy, whereas P had no effect on this measurement. As a consequence, the calculated left ventricular mass index was reduced by P throughout the study, but remained essentially unchanged by L until the twelfth month. Neither drug adversely affected fractional shortening. Cardiac output was significantly reduced by P, but unchanged by L, despite similar effects on heart rate by both drugs.

Thus, despite their similar effects on blood pressure, L and P had different effects on cardiac morphology, which may reflect varying responses to alpha-and beta-adrenergic blockade.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Kannel WB, Sorlie P. Left ventricular hypertrophy in hypertension: Prognostic and pathogenetic implications. The Framingham Study. In: Strauer BE, ed.The heart in hypertension. Berlin: Springer-Verlag, 1981:223–242.

    Google Scholar 

  2. Sen S, Tarazi RC. Regression of myocardial hypertrophy and influence of adrenergic system.Am J Physiol 1983;244:H97-H101.

    PubMed  Google Scholar 

  3. Ishise S, Pegram BL, Frohlich ED. Disparate effects of alpha-methyldopa and clonidine on cardiac mass and haemodynamics in rats.Clin Sci 1980;59:449–452.

    Google Scholar 

  4. Sen S, Tarazi RC, Khairallah PA, et al. Cardiac hypertrophy in spontaneously hypertensive rats.Circ Res 1974;35:775–781.

    PubMed  Google Scholar 

  5. Fouad FM, Nakashima Y, Tarazi RC, et al. Reversal of left ventricular hypertrophy in hypertensive patients treated with methyldopa. Lack of association with blood pressure control.Am J Cardiol 1982;49:795–801.

    PubMed  Google Scholar 

  6. Wollam GL, Hall WD, Porter VD, et al. Time course of regression of left ventricular hypertrophy in treated hypertensive patients.Am J Med 1983;75(Suppl 3A):100–110.

    Google Scholar 

  7. Tarazi RC, Sen S, Catecholamines and cardiac hypertrophy. In:Catecholamines and heart. Royal Society of Medicine International Congress.

  8. Laks MM, Morady F. Norepinephrine—the myocardial hypertrophy hormone.Am Heart J 1976;91:674.

    PubMed  Google Scholar 

  9. Laks MM, Morady F, Swan HJC. Myocardial hypertrophy produced by chronic subhypertensive doses of norepinephrine in the dog.Chest 1976;64:75–76.

    Google Scholar 

  10. Simpson P: Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an alpha1-adrenergic response.J Clin Invest 1983;72:732–738.

    PubMed  Google Scholar 

  11. Trimarco B, Wikstrand J: Regression of cardiovascular structural changes by antihypertensive treatment: Functional consequences and time course of reversal as judged from clinical studies.Hypertension 1984;6 (Suppl III) 111: 150–156.

    Google Scholar 

  12. White WB, Schulman P, Karimeddini K, et al. Regression of left ventricular mass is accompanied by improvement in rapid left ventricular filling following antihypertensive therapy with metoprolol.Am Heart J 1989;117:117–145.

    Google Scholar 

  13. Corea L, Bentivoglio M, Verdecchia P, et al. Left ventricular hypertrophy regression in hypertensive patients treated with metoprolol.Int J Clin Pharm Ther Toxicol 1984;22:365.

    Google Scholar 

  14. Sau F, Cherchi A, Seguro C. Reversal of left ventricular hypertrophy after treatment of hypertension by atenolol for one year.Clin Sci 1982;63 (Suppl 8):367s-369s.

    Google Scholar 

  15. Dunn FG, Ventura H, Messerli F, et al. Time course of regression of left ventricular hypertrophy in hypertensive patients treated with atenolol.Circulation 1987;76:254–258.

    PubMed  Google Scholar 

  16. Trimarco B, Ricciardelli B, De Luca N, et al. Effect of acebutolol on left ventricular haemodynamics and anatomy in systemic hypertension.Am J Cardiol 1984;53:791–799.

    PubMed  Google Scholar 

  17. Kaul V, Mohan JC, Bhatia ML. Effects of labetalol on left ventricular mass and function in hypertension—An assessment of serial echocardiography.Int J Cardiol 1984;5:461–469.

    PubMed  Google Scholar 

  18. Weiss RJ, Bent B. Diltiazem-induced left ventricular mass regression in hypertensive patients.J Clin Hypertens 1987;3:135–143.

    PubMed  Google Scholar 

  19. Leenen FHH, Smith PL, Farkas RM, et al. Vasodilators and regression of left ventricular hypertrophy. Hydralazine versus prazosin in hypertensive humans.Am J Med 1987;2:969–978.

    Google Scholar 

  20. Crawford MH, Grant D, O'Rourke RA, et al. Accuracy and reproducibility of new M-mode echocardiographic recommendations for measuring left ventricular dimensions.Calculation 1980;61:137–143.

    Google Scholar 

  21. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings.Am J Cardiol 1986;57:450–458.

    PubMed  Google Scholar 

  22. Inouye IK, Massie BM, Loge D, et al. Abnormal left ventricular filling: An early finding in mild to moderate systemic hypertension.Am J Cardiol 1984;53:120–126.

    PubMed  Google Scholar 

  23. Fouad FM, Tarazi RC, Gallagher JH, et al. Abnormal left ventricular relaxation in hypertensive patients.Clin Sci 1980;59(Suppl II):411s-414s.

    PubMed  Google Scholar 

  24. Reichek N, Devereux RB. Left ventricular hypertrophy: Relationship of anatomic, echocardiographic and electrocardiographic findings.Circulation 1981;63:1391–1397.

    PubMed  Google Scholar 

  25. Devereux RB, Savage DD, Sachs T, et al. Relation of hemodynamic load to left ventricular hypertrophy and performance in hypertension.Am J Cardiol 1983;51:171–176.

    PubMed  Google Scholar 

  26. Drayer JIM, Gardin JM, Weber MA, et al. Cardiac muscle mass during vasodilation therapy of hypertension.Clin Pharmacol Ther 1983;33:727–736.

    PubMed  Google Scholar 

  27. Wong M, Shah PM, Taylor RD. Reproducibility of left ventricular internal dimensions with M-mode echocardiography: Effects of heart size, body position and transducerangulation.Am J Cardiol 1983;47:1068–1074.

    Google Scholar 

  28. MacMahon SW, Hickey AJ, Wilcken DEC. M-mode echocardiography: Reproducibility of serial left ventricular measurements in subjects with normal ventricles and patients with congestive cardiomyopathy.Aust NZ J Med 1983;13:457–462.

    Google Scholar 

  29. Szlachcic J, Massie BM, Greenberg B, et al. Inter-test variability of echocardiographic and chest x-ray measurements: Implications for decision making in patients with aortic regurgitation.J Am Coll Cardiol 1986;7:1310–1317.

    PubMed  Google Scholar 

  30. Felner JM, Blumenstein BA, Schlant RC, et al. Sources of variability in echocardiographic measurements.Am J Cardiol 1980;45:995–1004.

    PubMed  Google Scholar 

  31. Szlachcic J, Tubau JF, Vollmer C, et al. Effect, of diltiazem on left ventricular mass and diastolic filling in mild to moderate hypertension.Am J Cardiol 1989;63:198–201.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cardiology Service of the V.A. Hospital of the University of California, San Francisco, CA, USA

    Jadwiga Szlachcic, W. Dallas Hall, Julio F. Tubau M. D., Vivian Porter, Carol Vollmer, Gary Wollam, Alan Hirsch & Barry Massie

  2. Department of Medicine and Cardiovascular Research Institute of the University of California, San Francisco, CA, USA

    Jadwiga Szlachcic, W. Dallas Hall, Julio F. Tubau M. D., Vivian Porter, Carol Vollmer, Gary Wollam, Alan Hirsch & Barry Massie

  3. Department of Medicine, Division of Hypertension, School of Medicine, Emory University, Atlanta, GA, USA

    Jadwiga Szlachcic, W. Dallas Hall, Julio F. Tubau M. D., Vivian Porter, Carol Vollmer, Gary Wollam, Alan Hirsch & Barry Massie

Authors
  1. Jadwiga Szlachcic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. Dallas Hall
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Julio F. Tubau M. D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Vivian Porter
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Carol Vollmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gary Wollam
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Alan Hirsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Barry Massie
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Szlachcic, J., Hall, W.D., Tubau, J.F. et al. Left ventricular hypertrophy reversal with labetalol and propranolol: A prospective, randomized, double-blind study. Cardiovasc Drug Ther 4, 427–433 (1990). https://doi.org/10.1007/BF01857749

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01857749

Key Words

Search

Navigation